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Individuals at risk of coronary heart disease (CHD) show multiple correlations across blood biomarkers.
Single nucleotide polymorphisms (SNPs) indexing biomarker differences could help distinguish causal
from confounded associations because of their random allocation prior to disease. We examined the associ-
ation of 948 SNPs in 122 candidate genes with 12 CHD-associated phenotypes in 2775 middle aged men (a
genic scan). Of these, 140 SNPs indexed differences in HDL- and LDL-cholesterol, triglycerides, C-reactive
protein, ﬁbrinogen, factor VII, apolipoproteins AI and B, lipoprotein-associated phospholipase A2, homocys-
teine or folate, some with large effect sizes and highly signiﬁcant P-values (e.g. 2.15 standard deviations at
P 5 9.2 3 10
2140 for F7 rs6046 and FVII levels). Top ranking SNPs were then tested for association with
additional biomarkers correlated with the index phenotype (phenome scan). Several SNPs (e.g. in APOE,
CETP, LPL, APOB and LDLR) inﬂuenced multiple phenotypes, while others (e.g. in F7, CRP and FBB)
showed restricted association to the index marker. SNPs inﬂuencing six blood proteins were used to evaluate
the nature of the associations between correlated blood proteins utilizing Mendelian randomization. Multiple
SNPs were associated with CHD-related quantitative traits, with some associations restricted to a single
marker and others exerting a wider genetic ‘footprint’. SNPs indexing biomarkers provide new tools for
investigating biological relationships and causal links with disease. Broader and deeper integrated analyses,
linking genomic with transcriptomic, proteomic and metabolomic analysis, as well as clinical events could, in
principle, better delineate CHD causing pathways amenable to treatment.
INTRODUCTION
Like many common disorders, coronary heart disease (CHD)
results from a complex interplay between environmental and
geneticfactors,complicatingtheidentiﬁcationofthecausalpath-
ways, and delaying the development of new treatments (1). By
1981, over 200 phenotypic and other differences had been
shown in those with, or at higher risk of CHD (2). Alterations
in circulating blood phenotypes (also referred to as
biomarkers) such as lipid and lipoprotein particles, proteins
involvedininﬂammationandcoagulation,aswellasmetabolites
and markers of oxidant stress, tend to cluster among those at
higher risk, making it difﬁcult to ascertain the nature and direc-
tion of biological relationships between biomarkers, and the
independent effect of any one biomarker on CHD risk (3).
These associations may be causal, but alternatively could arise
because they mark subclinical disease (reverse causation),
other causal factors (confounding) or some combination of
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cally a causal role in CHD for one blood phenotype
(LDL-cholesterol). This was achieved in large part by develop-
ing the HMG-CoA reductase inhibitor (statin) class of drugs
that reduce blood level of LDL-cholesterol and testing their
effects in randomized trials (4). However, the expense and risk
associated with the development of the many selective drugs
needed to target the vast array of blood phenotypes implicated
in CHD, currently precludes a comprehensive and systematic
approach to understanding their causal relevance and limits
translation of the basic science and epidemiological ﬁndings
into new treatments.
Many (if not all) of the circulating biomarkers associated
with CHD behave as heritable quantitative traits, and
common single nucleotide polymorphisms (SNPs) inﬂuencing
their variance are now being identiﬁed both by candidate gene
and genome wide studies (5–8). Unlike the associations
between biomarkers, or the association of biomarkers with
CHD risk, genetic associations should be protected from
reverse causation because genotype is an invariant character-
istic, such that there is a unidirectional ﬂow of information
from common genome variation to mRNA to protein to
complex phenotype and disease. Moreover, since genotype is
determined at random at conception, for SNPs affecting
CHD risk, intermediate phenotypes (such as blood markers),
residing off the causal pathway from SNP to disease, should
be balanced evenly among the different genotypic groups, as
they are in a randomized clinical trial, whereas biomarkers
that mediate the effect of genomic variation on disease risks
should differ by genotype. We hypothesized that SNPs,
which affect the variance in biomarkers linked to CHD,
could be used as unbiased tools with which to understand
their causal relevance and to explore the extent to which cor-
relation between multiple CHD-associated phenotypes are
affected by confounding. This principle of Mendelian ran-
domization has been applied to assess the causal role of indi-
vidual biomarkers with CHD risk (9,10). Here we applied
Mendelian randomization to help distinguish causal from con-
founded links between multiple biomarkers.
Formerly, association studies in the cardiovascular genetics
ﬁeld typed SNPs in a single gene or locus of interest. More
recently, genome wide association studies (GWAS) (5–7)
have extended the breadth of genetic information, but the
focus of these studies has been on a single continuous trait
or disease outcome, limiting the ability to address inter-
relationships among traits. We utilized a genotyping strategy
that exploits the recent ﬁnding that gene variants regulating
expression commonly reside in the vicinity of genes
(11–13), to build a panel of SNPs inﬂuencing variance in
one or more CHD-related biomarkers to investigate the
nature of the association between markers.
RESULTS
Between-phenotype correlations and associations
with CHD risk
In the prospective Northwick Park Heart Study II of 3102
initially healthy men followed prospectively for a median of
13.6 years, there were 296 deﬁnite fatal or non-fatal
CHD events. Measures of 14 intermediate phenotypes were
available, six with annual repeat measures (on six occasions)
and single measures for the remaining eight (Supplementary
Material, Table S1). To delineate the potential for confounding
in the associations of blood markers and other phenotypes with
CHD, we assessed between-phenotype correlations. Men who
developedaCHDeventonfollow-upexhibitedmultiplepheno-
types which distinguished them from those who remained
disease free, and these differences were highly inter-correlated
(Fig. 1 and Supplementary Material, Table S1). Seventy-two of
the 105 possible pair-wise correlations between blood markers
and other CHD-related traits were signiﬁcant with a
P-value   0.05 (68 traits signiﬁcant with a P-value   0.01),
which signiﬁcantly exceeds the ﬁve expected by chance alone
(P , 1   10
28 for observed versus the expected). Many of
the associations were highly signiﬁcant and the absolute
P-values are provided in Supplementary Material, Figure S1.
Genic scan
We genotyped 948 SNPs in 122 genes chosen for a high prior
probability of association with CHD-associated phenotypes in
NPHS II based on prior association studies and biological evi-
dence. A total of 134 SNP-trait associations were identiﬁed
distributed as follows: 12 SNPs in APOB, LDLR, PCSK9,
APOE-C1-C2-C4 and LRP5 with total cholesterol; 23 SNPs
in APOB, LDLR, APOE-C1-C2-C4, PLA2G7, PCSK9,
CDKN, EXT2, C3 and GSTM3 with LDL-cholesterol and 6
SNPs in CETP, ALOX5AP APOA5-A4-C3-A1, LIPC and
LPL with HDL cholesterol. Thirty-seven SNPs in LPL,
APOA5-A4-C3-A1, TGFB1, PECAM, IL6R, C2, ILRN1, INS,
LDLR, F7, ANGPTL4, APOB, GCKR, IL18RAP, PCSK9 and
LRP5 were associated with triglyceride levels. Nine SNPs in
LIPC, CETP, ALOX5AP, APOA5-A4-C3-A1, APOE-C1-
C2-C4, IGF2, C3 and LPL were associated with apoAI
levels. Twelve SNPs were associated with apoB levels; these
were in APOE-C1-C2-C4, APOB, LDLR, PCSK9, LPL
GSTM4 and EXT2. Three SNPs in APOE-C1-C2-C4 and
NOS3 were associated with Lp-PLA2 activity. Seven SNPs
in the F7 gene itself and one in PROCR exhibited very
highly signiﬁcant association with blood factor VII level.
Seven SNPs in the FIBA-B-G cluster, UCP3, GSTM4 and
the APOA5-A4-C3-A1 cluster were associated with ﬁbrinogen.
Five SNPs from two genes, APOE-C1-C2-C4 and CRP, were
associated with C-reactive protein. These represented 98
unique SNPs in 36 genes. The full range of SNP-phenotype
associations is illustrated in Figure 2A-l and summarized in
Supplementary Material, Table S2. Because of the gene-
centric strategy, the SNP-phenotype associations clustered
within genes, even though SNPs had been chosen as tag
SNPs. These associations remained signiﬁcant even after the
LD structure between them was considered (see Supplemen-
tary Material, Table S6). Thus, for some genes, several
SNPs remain associated with the blood biomarker, supporting
the possibility of independent associations at a given locus, as
we noted previously for CRP (14).
Signiﬁcance and validity of the genetic associations. Despite
the moderate size of the data set, nearly 13% (18 of 140) of the
associations achieved the level of signiﬁcance conventionally
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27). Sixteen of the 134 SNPs
were also directly typed and were signiﬁcant hits in recent
GWASs of blood markers (Table 1) including: rs6511720 in
LDLR (5,15), SNPs in LD with rs42935/rs7412 with APOE
SNPs and LDL-cholesterol (5,6); as well as rs708272 in
CETP with HDL-cholesterol (5,6,15).
Notably, for each genic scan where the outcome was a
single-protein phenotype at least one cis-acting SNP in the
gene encoding the cognate protein was always identiﬁed
among the most signiﬁcantly associated SNPs, with P-values
generally between 10
24 and 10
27, but as extreme as 10
2140
for rs6046 in F7 and blood factor VII levels. In line with a
recent report, we refer to these genes as protein quantitative
trait genes (pQTGs) (8) and the SNPs as pQTSNPs.
Effect size. The effect of each associating SNP was expressed
both in terms of the proportion of the trait variance explained,
and as the standardized mean difference in trait level between
subjects homozygous for the alternative alleles (Fig. 3A and
B), allowing effect sizes to be expressed on a common
scale. When considered solely in terms of the variance, the
effect size for individual SNPs appeared modest with only
two SNPs in the F7 gene, each explaining 20% of the var-
iance of factor VII (Fig. 3A), both independently signiﬁcant
of each other. However, for 28 SNPs (24%) crossing the
FDR threshold, the difference in average trait values
between homozygous subjects exceeded 0.5 standard devi-
ations (SD) of the population distribution, with the difference
exceeding 0.75 SD for 17 SNPs. For 10 SNPs, the difference
in trait values between homozygous subjects exceeded 1 SD,
with the most extreme differences for a common allele
(.5%) being 2.15 SD for the difference in Factor VII levels
between subjects homozygous for alternative alleles of
rs6046 in F7 (Fig. 3C).
Phenome scan
We next assessed the association of top ranking genes from the
genic scan with additional phenotypes and the ﬁndings are
illustrated graphically in Figure 4A–H by means of
phenome plots. The phenome scan examines the relationship
between variants of the gene of interest and all the intermedi-
ate traits studied. This is in contrast with the genic scan where
each intermediate trait of interest is considered and all the
genetic variants associated with it are examined as a Manhat-
tan plot. In the phenome scan, the gene of interest is depicted
as an ellipse and the associated phenotypic traits as circles
radiating out from it. The circle diameter of each phenotype
is a measure of the variance of the phenotype explained by
the variation encompassing all SNPs in that gene of interest,
with the value (coefﬁcient of determination, R
2) given along-
side the relevant circle. In addition, for each phenotype, the
distance from the gene is a measure of the signiﬁcance
value, adjusted for multiple testing using the false discovery
rate (FDR), for the SNP with the strongest signal within the
gene of interest. In the phenome scan, we applied a more strin-
gent signiﬁcance threshold, focusing on those phenotypes
crossing an FDR adjusted P-value of ,0.1. An inner square
of dotted lines has been drawn at this threshold with the
gene of interest and the phenotype(s) with FDRs ,0.1 being
shown in the enlarged subpanel.
SNPs in certain pQTGs (e.g. in F7, CRP and the FIBA-B-G
cluster) exhibited phenotypic effects that were restricted to an
alteration only in the cognate gene product. The restricted
Figure 1. Correlations between multiple phenotypes linked to CHD in 2775 men from the NPHSII study. Values in cells indicate Pearson’s correlation coefﬁ-
cient R.  P , 0.01,   P , 0.001 (see colour code). Baseline and ﬁve repeat measures were available for cholesterol, triglycerides (TG), coagulation factor VII
(FVIIc), ﬁbrinogen, blood pressure (BP), smoking and body mass index (BMI) and single measures for the remaining traits.
Human Molecular Genetics, 2009, Vol. 18, No. 12 2307nature of the SNP effects for these genes contrasted sharply
with the extensive direct phenotypic associations of the pro-
teins they encode (Fig. 1).
SNPs in several other genes and regions, involved in lipid
and lipoprotein transport or metabolism, appeared to exert
more diverse phenotypic effects. For example, SNPs in the
APOE-C1-C2-C4 cluster were associated with three lipid
and lipoprotein traits (total- and LDL-cholesterol, apoB) con-
sistent with previous observations (16). The phenome scan for
APOE-C1-C2-C4 also revealed a strong association of SNPs
in this region with the hepatocyte-derived inﬂammation
marker C-reactive protein (CRP), but interestingly not with
another hepatocyte-derived acute phase protein, ﬁbrinogen
(Fig. 4F). The APOE–CRP association was highly signiﬁcant
(P ¼ 1.28   10
210) and the effect size was at least as large as
the effect of cis-acting SNPs in the gene on CRP itself (Sup-
plementary Material, Table S2). This association is also vali-
dated by several candidate gene studies and by two recent
GWAS (17,18). In addition, APOE-C1-C2-C4 SNPs
rs429358/rs7412, which together deﬁne the E2, E3 and E4
alleles, were also strongly associated with Lp-PLA2 activity
(P ¼ 2.55   10
214), and explained almost 4% of the variance
in this trait, with a 0.21 SD difference in Lp-PLA2
activity between homozygous subjects. The association of
APOE-C1-C2-C4 SNPs with apoAI was also evident but
because of the more modest levels of signiﬁcance, these
associations are not shown in Figure 4F. The CETP SNP
rs708272, which exhibited the strongest association with
Figure 2. Associations of 860 SNPs by chromosome with 12 blood phenotypes. The horizontal line indicates a critical FDR threshold of 0.2, approximately
equivalent to a P-value , 10
23.
2308 Human Molecular Genetics, 2009, Vol. 18, No. 12HDL-cholesterol in the genic scan, showed additional
associations with apoAI (Fig. 4E). These associations have
been corroborated by meta-analyses of genetic association
studies (19).
SNPs in the APOA5-A4-C3-A1 (Fig. 4A) cluster also exhib-
ited diverse effects on blood lipid and lipoprotein phenotypes
as did variants in the LDLR gene (Fig. 4B). For the APOA5
gene cluster and LPL, the anticipated association with trigly-
cerides was seen (20). Furthermore, for the APOA5 cluster,
although the previously reported association with apoAI was
evident, with an FDR of 0.14 it was not included in the
enlarged phenome scan where the FDR cut-off was 0.1.
Table 1. SNPs from the current study showing replication with GWAS hits
Phenotype Previous GWAS hit (alternate phenotype
previously showing association)
rs Gene P-value FDR Common versus
rare HMZ
% R
2 trans MAF
Triglycerides (6)(LDL) rs6589566 APOA5-A4-C3-A1 1.98E205 0.01 0.633 0.9 7.0
(15) rs328 LPL 2.85E204 0.03 0.189 0.7 10.9
Cholesterol (15) rs6511720 LDLR 9.38E208 0.01 0.432 1.2 12.3
(5,7,15), (42)(AD), (43)(AD) rs4420638 APOE-C1-C2-C4 2.78E206 0.01 0.370 1.0 19.1
LDL (5,15) rs6511720 LDLR 3.83E206 0.01 0.776 1.6 12.3
(5,7,15,42)(AD), (43)(AD) rs4420638 APOE-C1-C2-C4 8.72E204 0.11 0.344 0.9 19.1
ApoB (15)(LDL) rs11591147 PCSK9 6.43E205 0.03 3.055 0.9 0.9
(15)(LDL); (5)(LDL) rs6511720 LDLR 1.23E203 0.14 0.195 0.6 12.3
(15)(TG), (5)(TG), (6)(LDL), (17)(CRP) rs780094 GCKR 3.21E203 0.20 0.207 0.5 37.8
ApoAI (15)(HDL) rs1800588 LIPC 4.72E205 0.03 0.332 1.0 20.5
(15)(HDL, TG) rs328 LPL 2.14E203 0.19 0.575 0.5 10.3
CRP (7)(LDL), (15)(LDL), (5)(LDL),
(42)(AD), (43)(AD)
rs4420638 APOE-C1-C2-C4 2.20E207 0.01 0.404 1.4 19.1
(17) rs3091244 CRP 2.74E204 0.05 0.182 0.7 5.5
Lp-PLA2 (7)(LDL), (24)(LDL), (5)(LDL),
(42)(AD) (43) (AD)
rs4420638 APOE-C1-C2-C4 1.42E206 0.01 0.490 1.48 19.1
Homocysteine (23)(CHD) rs6922269 MTHFR 2.78E205 0.03 0.375 1.5 31.1
FVII (15)(HDL, TG) rs328 LPL 2.98E204 0.04 0.102 0.0 10.3
The phenotype associated with the SNP from the GWAS, if different from the current study is given in brackets.
LDL, low density lipoprotein; TG, triglycerides; AD, Alzheimer’s disease, CRP, C-reactive protein, HDL, high density lipoprotein.
Figure 3. The relationship between minor allele frequency and effect size for SNP-phenotype associations exceeding the pre-speciﬁed FDR threshold. Effect size
was expressed as: (A) variance and (B) as the standardized mean difference for comparisons of homozygous subjects. (C) Examples of SNPs with extreme effects
assessed in terms of standardized mean difference.
Human Molecular Genetics, 2009, Vol. 18, No. 12 23092310 Human Molecular Genetics, 2009, Vol. 18, No. 12pQTSNPs as tools to distinguish causal from non-causal
associations between blood protein phenotypes
Because cis-acting variants in a gene encoding a protein trait
(pQTSNPs) provide a highly speciﬁc instrument with which
to investigate the causal effects of the encoded protein (utiliz-
ing the principles of Mendelian randomization), we used the
most strongly associating pQTSNPs for apoAI, apoB, CRP,
factor VII, ﬁbrinogen and lipoprotein-associated phospho-
lipase A2 (Lp-PLA2) as their unconfounded proxies to help
evaluate confounding in the directly observed associations
between these proteins (Supplementary Material, Fig. S2)
and (Fig. 5).
In Figure 5, the magnitude of the association between
protein phenotypes is illustrated for a difference in the mean
values of the top versus bottom tertile of the index phenotype,
approximately equal to a 2 SD difference. Thus, a 2 SD differ-
ence in factor VII is associated with a standardized mean
difference in apoB, CRP and ﬁbrinogen of 0.41, 0.31 and
0.25, respectively. Individuals homozygous for the variant
Figure 4. Continued.
Figure 4. Phenome plots. The gene of interest is depicted as an ellipse and the associated phenotypes traits as circles. The circle diameter is a measure of the
variance of the phenotype explained by the variance of the genotypes (R
2) of all the SNPs in the gene of interest. The numbers given next to each phenotype are
the percent values of the coefﬁcient of determination R
2 of the phenotype for the combined effect of all the SNPs of the gene. The distance from the gene to each
phenotype is a measure of the signiﬁcance value, adjusted for multiple testing using the FDR, for the SNP with the strongest signal within the gene of interest.
The number shown next to each edge is the percent value of the FDR adjusted P-value with its length measured from ellipse (gene) centre to circle (phenotype)
centre. The dashed line represents those phenotypes which fall within the ,0.1 FDR with the gene of interest. Those phenotypes and the gene are then expanded
alongside in the accompanying ﬁgure so that details can be seen more clearly. For the phenome scan, an even more stringent FDR adjusted P-value of ,0.1 to
reduce further the risk of false-positive association. (Hcy, homocysteine; Flt, folate; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass
index).
Human Molecular Genetics, 2009, Vol. 18, No. 12 2311allele rs6046 exhibited a 2.15 SD higher blood factor VII level
which is approximately equivalent to the difference in levels
between the top and bottom tertile of the Factor VII
distribution. However, the point estimate of the effect of
rs6046 on levels of apoB and ﬁbrinogen was null and therefore
discordant from that expected from the directly observed
association of factor VII with these phenotypes if this was a
causal link. The point estimate of the association of rs6046
with CRP was close to that expected from a causal association,
but the conﬁdence limits spanned the null. Thus, the simplest
explanation of these ﬁndings is that the factor VII is unlikely
to cause an alteration in apoB or ﬁbrinogen, but a causal effect
on CRP is possible and would require a larger sample to
conﬁrm or refute reliably. For the majority of other pairwise
comparisons, the point estimates of the genetic effect were
either null or directionally opposite from that expected from
a causal link, though because of wide conﬁdence limits,
larger studies would be required to provide deﬁnitive evi-
dence.
The relationship between minor allele frequency and stan-
dardized effect size for 80% statistical power is plotted in Sup-
plementary Material, Figure S3. The study can detect effects at
0.4 SD for any SNP with a MAF . 20%, but can only detect
large effects (.0.8SD) from a SNP with ,10% MAF.
DISCUSSION
Gene centric (genic scan) to identify variants inﬂuencing
multiple blood biomarkers
We developed a genotyping strategy aimed at providing a
suite of tools to help evaluate the nature of associations
Figure 5. The magnitude of the association between protein phenotypes is illustrated as the mean difference of the standardized levels of the phenotype between
top and bottom tertile of the index phenotype, approximately equal to a 2 SD difference. When the most strongly associating SNP in the pQTGs is considered, the
mean difference is between the two homozygote groups. (A) apoAI, (B) apoB, (C) CRP, (D) coagulation factor VII, (E) ﬁbrinogen, and (F) Lp-PLA2.
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CHD using Mendelian randomization. We used a gene-centric
approach based on genes with a high prior probability of
association with the traits of interest in NPHSII. This proved
to be an efﬁcient strategy providing a high yield
of SNP-biomarker associations even at conservative levels
of statistical signiﬁcance and a stringent FDR threshold,
with134 SNP-associations out of the 948 SNPs ( for which
genotype was available), distributed among 36 genes.
These ﬁndings are in keeping with emerging data from
GWAS of gene expression (11), blood proteins (8), lipid and
other non-protein traits (5,6) and metabolic proﬁles (21).
Together these provide strong evidence that regulatory SNPs
are found commonly in the vicinity of genes and validate a
gene-centric approach to identify genotypes inﬂuencing mul-
tiple blood traits linked to CHD and other complex disorders.
The scope and breadth of gene-centric studies is likely to be
extended by the emergence of comprehensive disease-speciﬁc
gene-centric custom SNP arrays such as the ITMAT/BROAD/
CARE (IBC) ‘cardio-metabolic chip’ that covers around 2100
genes from lipid, inﬂammation, coagulation, oxidants stress,
matrix and other pathways linked to CHD (http://
bioinf.itmat.upenn.edu/cvdsnp/index.php) (22).
Although the genotyping strategy was focused on candidate
genes, some novel associations also emerged, e.g. associations
of SNPs in APOE with Lp-PLA2 activity. Lp-PLA2 is phys-
ically associated with LDL particles where it could exert
pro-atherogenic actions through hydrolysis of oxidized phos-
pholipids to lysophosphatidylcholine and oxidized free fatty
acids. Although APOE-C1-C2-C4 SNPs also inﬂuence the
level of circulating LDL, and theoretically might therefore
inﬂuence Lp-PLA2 activity simply through an effect on the
concentration of this particle, other SNPs that affected
LDL-cholesterol concentration (e.g. APOB, and LDLR) were
not associated with Lp-PLA2 activity, suggesting a more
direct link between apoE and Lp-PLA2 that is worthy of
further investigation.
Though 16 of the genetic associations we identiﬁed have
been corroborated by both candidate gene studies and
GWAS, and can be considered robust, the relevance and
utility of such associations has been debated given that the
proportion of the total variance in a continuous trait explained
by common alleles can be small (commonly ,5%) (9).
However, our study suggests that interpretations based on
this metric alone may provide an incomplete picture. For
many SNPs whose contribution to the variance in a phenotype
was small, we found evidence of a substantial effect size when
expressed in terms of the standardized mean difference in bio-
marker level between homozygous subjects. We noted many
examples of differences over 0.5 SD, and several of over 1
SD for variants inﬂuencing triglycerides, apoB, Lp-PLA2
and factor VII. These would be considered very substantial
effects for a drug designed to modify the level of one of
these biomarkers. For example, standard doses of statin
drugs in clinical use reduce LDL-cholesterol by about 1 SD
(4). However, even SNPs with small effect could be important,
because therapies that might arise from the genetic ﬁndings
could be designed to have much more potent effects than the
natural genetic variation. For example, variants in HMGCR
that encodes the target enzyme for cholesterol-lowering statin
drugs, affect LDL-cholesterol but did not emerge among the
top-ranking SNPs in recent GWAS for CHD (23), although
an association of these SNPs with CHD risk has been sub-
sequently reported (24).
We also noted a trend for less common genetic variants to
exert larger effects when expressed in terms of the standar-
dized mean difference but not in terms of the variance
(Fig. 3). This ﬁnding is consistent with the emerging paradigm
of an inverse association between allele frequency and
penetrance (25).
Phenome scans and use of SNPs as tools to distinguish
causal from confounded links between biomarkers
It has been common for genome wide and candidate gene
association studies to focus on SNP associations with a
single trait or disease outcome, but the pathway from
disease-relevant SNP to disease potentially involves multiple
phenotypic perturbations both in series and in parallel. It is
therefore of interest not only to determine the full spectrum
of SNPs affecting a single trait or outcome, but also the
range of phenotypes altered by single SNP or gene. (26).
We noted several genes and SNPs with effects on multiple cir-
culating biomarkers, suggesting that some genes may have a
broad footprint of effects on the proteome and metabolome.
This is often referred to as pleiotropy but it may be important
to distinguish between the multiplicity of effects arising from
the generation of more than one protein product as a result of
alternative splicing of an mRNA transcript of a gene, from the
those arising from the broad ranging downstream effects of a
single protein product (such as an enzyme or transporter)
involved in lipid and lipoprotein pathways (e.g. apoE or cho-
lesteryl ester transfer protein), which is the more likely expla-
nation for the range of SNP effects observed in the present
study.
Though some SNPs exerted a broad footprint of phenotypic
effects, for others (e.g. in F7 and FIB), there was a more
tightly restricted association of SNPs in the encoding gene
with the cognate protein but no other trait, despite the exten-
sive directly observed correlations between the protein itself
and other markers. This contrast between the range of genoty-
pic and phenotypic associations is likely to arise from the ran-
domized assignment of alleles, and the non-randomized
(clustered) association of phenotypes (see Fig. 1) (27,28).
This renders SNPs in certain pQTGs particularly well suited
as proxies (instruments) with which to investigate the causal
relevance for CHD of the proteins they encode because, in
contrast to the proteins themselves, the genetic associations
should not be prone to confounding or reverse causation bias
(29–31).
For example, CRP is strongly correlated with ﬁbrinogen
(R
2 ¼ 0.43; Fig. 1). This association could arise because of a
causal relationship (in either direction) or because of a
common association of both these biomarkers with another
factor. This makes it difﬁcult to assess whether CRP and ﬁbri-
nogen lie on the same causal pathway to CHD, and whether it
is legitimate to make statistical adjustment for ﬁbrinogen in
the many observational associations of CRP with CHD (and
vice versa). Statistical adjustment, which is the orthodox
approach to dealing with confounding in observational
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CRP with CHD was not mediated (even in part) by an
elevation in the level of ﬁbrinogen. The absence of an associ-
ation of CRP SNPs with ﬁbrinogen level (or FIBA-B-G
with CRP level) (Fig. 4I), which is consistent with the
ﬁndings from other studies of these variants (29,32) indicates
that CRP and ﬁbrinogen do not exhibit a direct causal
association with one another and that statistical adjustment
is appropriate in observational studies of these biomarkers
with CHD.
Whereas cis-acting SNPs in the encoding gene offer the
most speciﬁc genetic instrument with which to assess the
causal role of a protein in CHD, there may not be a single
best instrument for a non-protein trait such as the level of
HDL- or LDL-cholesterol that are inﬂuenced by a number of
different genes encoding enzymes and transporters. We
noted SNPs from a range of genes inﬂuencing the same lipid
trait (Supplementary Material, Table S2). Validation of the
use of multiple SNPs for such causal analysis for non-protein
traits is illustrated using the example of LDL-cholesterol, the
only blood phenotype for which a causal role in CHD has
already been ﬁrmly established.
Rare variants in LDLR, APOB and gain-of-function
mutations in PCSK9 result in extreme elevations in
LDL-cholesterol, as in Familial Hypercholesterolemia (33),
while PCSK9 loss-of-function variants are associated with
very low LDL-cholesterol levels and are protective of CHD
(34). In addition, common variants of APOE (16), PSRC1/
CELSR/ SORT1, LDLR and PCSK9 (5–7,35), including
some tagged by SNPs in the current study that cause more
modest changes in LDL-cholesterol, have also been associated
with alterations in risk of CHD (5,34,35), with the genetic
effects on disease risk directionally concordant and in pro-
portion to the size of the effect on LDL-cholesterol.
Implications of the current ﬁndings for future work
The principles applied in the current study could be extended
to incorporate rare SNPs or copy number variants, or regulat-
ory SNPs remote from genes using denser new generation
GWAS platforms. The phenotypes evaluated could be
extended both proximally to include mRNA expression and
more distally to include more complex phenotypes linked to
CHD such as carotid-intima media thickness or measures of
coronary artery calciﬁcation. The breadth of the approach
could also be extended laterally at the level of protein and non-
protein phenotypes using proteomic and metabolomics,
respectively. Our study highlights the importance of well-
phenotyped population samples and emphasizes the require-
ment for large sample sizes. However, whether this approach
will aid in developing causal networks and genotype: pheno-
type maps, as outlined recently by Rockman, remains to be
seen (36).
In summary, we demonstrate how integrating information
on genotype and blood phenotypes in humans can be used to
construct association networks with a high-level of credibility,
due to the particular properties of genetic variants, which are
randomly allocated and unmodiﬁable by disease process, fea-
tures which are not shared by any other natural biological
exposure (e.g. mRNA levels or protein levels) Our study
emphasizes the potential translational application emerging
from the recent genomic advances.
MATERIAL AND METHODS
Study design and phenotypic measures
The Northwick Park Heart Study II (NPHSII) is a prospective
study of 3012 healthy middle-aged men aged 50–64 years at
recruitment, sampled from nine UK general practices
between 1989 and 1994 (37). Men were free from disease at
the time of recruitment, and information on lifestyle habits,
height, weight and blood pressure were recorded at baseline
and on subsequent prospective follow-up. Measures were
made of at least 15 circulating blood factors associated with
CHD risk that included both circulating proteins (CRP, lipid
fractions and non-protein metabolites), all the measures
being obtained before the development of clinical events,
with repeated measurements available for some factors (Sup-
plementary Material, Table S1). A DNA repository was estab-
lished using samples from 2775 men obtained at the time of
recruitment. By December 2005, after a median follow-up of
13.6 years, there had been 296 deﬁnite fatal or non-fatal
CHD events (230 in 2401 of the genotyped sample). Full
details of recruitment, measurements, follow-up and deﬁ-
nitions of incident disease have been reported elsewhere (37).
Genic scan
A customized Illumina 768 SNP genotyping array was
assembled to comprehensively capture common genetic vari-
ation in more than 76 genes chosen (1): for their involvement
in the following pathways linked to CHD risk; lipid metab-
olism (10 genes), inﬂammation (23 genes), oxidative stress
(13 genes), thrombosis and haemostasis (3 genes); (2) for a
previously described association with the risk of CHD or
type 2 diabetes (T2D) mellitus, including SNPs from a
recent whole-genome analysis of T2D which marginally
failed the P , 10
27 signiﬁcance threshold for genome wide
signiﬁcance (Prof Philippe Froguel, personal communication);
or (3) for their ability to tag copy number variation (38). For
each gene or region, tagging (t) SNPs, optimized for the Illu-
mina platform, was selected using HapMap, applying an R
2
threshold of 0.8 with a minor allele frequency threshold of
0.04. Where possible, coding (c) SNPs were included in the
tag set. Illumina Goldengate SNPs with pre-optimized assays
were chosen where possible, however roughly 10% of the
chosen SNPs failed the assay design. A complete list of
genes selected and the tSNPs for each gene for which geno-
type was available is shown in Supplementary Material,
Tables S3 and S5. Genotypes from the Illumina array were
supplemented with information on 173 SNPs in a further 82
genes previously typed in this data set (Supplementary
Material, Tables S4 and S6). SNPs were examined for associ-
ations with 12 blood phenotypes available in NPHSII of which
six were protein phenotypes (CRP, ﬁbrinogen, apoAI, apoB,
Lp-PLA2 and factor VII) and six were non-protein metabolic
phenotypes (total-cholesterol, HDL- and calculated
LDL-cholesterol, triglycerides, homocysteine and folate). We
refer to this as a genic scan to distinguish the focused high
2314 Human Molecular Genetics, 2009, Vol. 18, No. 12SNP density, gene-centric approach used here from broader,
generally lower SNP density, genome-wide analyses.
Phenome scan
We examined the effect of the genes containing the highest
ranking SNPs from the genic scan on additional blood bio-
markers beyond the index trait and the results are illustrated
by means of a phenome plot (vide infra). These ﬁndings are
summarized by means of phenome plots that summarize the
associations of SNPs in a gene with blood marker(s) both in
terms of the FDR q-value (vide infra) and proportion of the
variance of the trait explained, using a stepwise regression
to ﬁnd the adjusted coefﬁcient of determination (adjR2)
under the model of best ﬁt.
Statistical analysis
Phenotypesweretestedfordeviationfromthenormalandtrans-
formed where appropriate, using the Box-Cox transformation.
Pair-wise linear relationships between blood phenotypes were
tested using Pearson correlation. If the phenotypic variant was
measured once in the study, an ANOVA was used to test for
its association with genotype. Where multiple measurements
wereavailable,theaveragevalueoftheavailablemeasurements
wascalculatedandageneral linearmodelwasﬁttedthroughthe
data using indicator variables. The regression coefﬁcients
obtained for the indicator variables compared to the reference
category were assessed for signiﬁcance using a Wald test.
Based on the number of hypotheses tested, a FDR adjusted
P-value was calculated using the methodology of Benjamini
and Hochberg (39). Deﬁning FDR as the proportion of falsely
rejected hypotheses, i.e. for which the null was actually true,
this new P-value, known as the q-value (40), is the minimum
FDR when rejecting a null hypothesis from a list of tested
null hypothesis, conditioned on at least one positive ﬁnding
having occurred. For the construction of the phenomic plots, a
stepwise regression was used to ﬁnd the adjusted coefﬁcient
of determination (adjR
2) under the model of best ﬁt. The
number of independent loci associated with each phenotype
was calculated using the LD-based result clumping procedure
in PLINK (v1.05, http://pngu.mgh.harvard.edu/purcell/plink/
(41). An extremely conservative R
2 of 0.1% was used to
clump SNPs, identiﬁed previously as statistically signiﬁcant,
in independent loci.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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